培高利特替代溴隐停治疗垂体泌乳素腺瘤

The effect of pergolide mesylate instead of bromocryptine on patients with prolactinomas

目的 探讨用培高利特替代溴隐停治疗对溴隐停耐药的垂体泌乳素瘤患者。方法 对 3 2例服大剂量溴隐停无明显疗效的患者改用培高利特治疗 ,观察治疗前后患者血泌乳素水平、月经、生殖情况。结果 改用培高利特治疗后 2 9例患者 (90 .6% )血泌乳素降至正常 ,恢复正常月经 ,其中 2 6例患者性腺激素也恢复正常 ,已婚妇女中 2 4例 (82 .8% )妊娠 ,3例 (9.4% )血泌乳素水平下降不满意 ,临床症状无改善。

Objective To investigate the effect of pergolide mesylate on patients who were resistant to bromocryptine.Methods 32 patients who were resistant to bromocryptine were treated with pergolide mesylate (17.5～20 mg/day).The serum prolactin level was detected and their menstruation and pregnancy were observed before and after the treatment. Results The results showed that after the treatment the serum prolactin declined to normal in 29 patients (90.6%) and menstruation recovered and galactostasis occurred ,among which serum gonad hormone in 26 patients returned to normal. 24 married patients (82.8%) became pregnant later. The serum prolactin level in 3 patients did not return to normal although the dose was increased and the clinical symptoms in those patients showed no improvement.Conclusion Patients with prolactinomas who are resistant to bromocryptine can be treated with pergolide mesylate instead of bromocryptine. \[